Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)

The hydrolysis of [Ru(η⁶-p-cymene)Cl₂(PTA)] (PTA = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decanephosphine; RAPTA-C) was studied using UV-visible (UV-vis) spectrophotometry and NMR spectroscopy. In analogy to in silico studies, [Ru(η⁶-p-cymene)Cl(H₂O)(PTA)]⁺ was found to be the most abundant hydrolysis product, although the dihydrolysed species [Ru(η⁶-p-cymene)(OH)(H₂O)(PTA)]⁺ and the dichloro compound are present. Rate constants for the different aquation and anation steps and the equilibrium constants were determined. Hydrolysis is suppressed at high chloride concentrations. These results have important implications on the mode of action of the RAPTA drug candidates.     

Ruthenium(II) arene complexes containing four- and five-membered monoanionic O,O-chelate rings

Optimization of the design of half-sandwich organometallic Ru^II arene complexes as anticancer agents depends on control of ligand exchange reactions. We have studied the aqueous chemistry of complexes containing O,O-chelate rings. The presence of the four-membered O,O-chelate ring from acetate (AcO) in [η⁶-p-cymene)Ru(AcO)Cl] was confirmed by X-ray crystallography, but in solution the acetate ligand was labile and the hydroxo-bridged dimer [((η⁶-p-cymene)Ru)₂(μ-OH)₃]⁺ readily formed. The dimer was relatively unreactive towards 9-ethyl guanine. The tropolonato (trop) complex [(η⁶-p-cymene)Ru(trop)Cl] was stable in aqueous media and the X-ray crystal structure of the aqua adduct [(η⁶-p-cymene)Ru(trop)(H₂O)]CF₃SO₃, containing a five-membered O,O-chelate ring from trop, was determined. [(η⁶-p-cymene)Ru(trop)Cl] reacted with guanosine to form N7 adducts and with adenosine to form both N7 and N1 adducts. Competitive reactions with guanosine and adenosine gave rise to guanosine:adenosine adducts in a ca. 1.3:1 mol ratio.     

Interactions of arene-Ru(II)-chloroquine complexes of known antimalarial and antitumor activity with human serum albumin (HSA) and transferrin

The interactions of π-arene-Ru(II)-chloroquine complexes with human serum albumin (HSA), apotransferrin and holotransferrin have been studied by circular dichroism (CD) and UV-Visible spectroscopies, together with isothermal titration calorimetry (ITC). The data for [Ru(η⁶-p-cymene)(CQ)(H₂O)Cl]PF₆ (1), [Ru(η⁶-benzene)(CQ)(H₂O)Cl]PF₆ (2), [Ru(η⁶-p-cymene)(CQ)(H₂O)₂][PF₆]₂ (3), [Ru(η⁶-p-cymene)(CQ)(en)][PF₆]₂ (4), [Ru(η⁶-p-cymene)(η⁶-CQDP)][BF₄]₂ (5) (CQ: chloroquine; DP: diphosphate; en: ethylenediamine), in comparison with CQDP and [Ru(η⁶-p-cymene)(en)Cl][PF₆] (6) as controls demonstrate that 1, 2, 3, and 5, which contain exchangeable ligands, bind to HSA and to apotransferrin in a covalent manner. The interaction did not affect the α-helical content in apotransferrin but resulted in a loss of this type of structure in HSA. The binding was reversed in both cases by a decrease in pH and in the case of the Ru-HSA adducts, also by addition of chelating agents. A weaker interaction between complexes 4 and 6 and HSA was measured by ITC but was not detectable spectroscopically. No interactions were observed for complexes 4 and 6 with apotransferrin or for CQDP with either protein. The combined results suggest that the arene-Ru(II)-chloroquine complexes, known to be active against resistant malaria and several lines of cancer cells, also display a good transport behavior that makes them good candidates for drug development.     

Arene-Ru(II)-chloroquine complexes interact with DNA, induce apoptosis on human lymphoid cell lines and display low toxicity to normal mammalian cells

The complexes [Ru(η⁶-p-cymene)(CQ)Cl₂] (1), [Ru(η⁶-benzene)(CQ)Cl₂] (2), [Ru(η⁶-p-cymene)(CQ)(H₂O)₂][BF₄]₂ (3), [Ru(η⁶-p-cymene)(en)(CQ)][PF₆]₂ (4), [Ru(η⁶-p-cymene)(η⁶-CQDP)][BF₄]₂ (5) (CQ = chloroquine base; CQDP = chloroquine diphosphate; en = ethylenediamine) interact with DNA to a comparable extent to that of CQ and in analogous intercalative manner with no evidence for any direct contribution of the metal, as shown by spectrophotometric and fluorimetric titrations, thermal denaturation measurements, circular dichroism spectroscopy and electrophoresis mobility shift assays. Complexes 1-5 induced cytotoxicity in Jurkat and SUP-T1 cancer cells primarily via apoptosis. Despite the similarities in the DNA binding behavior of complexes 1-5 with those of CQ the antitumor properties of the metal drugs do not correlate with those of CQ, indicating that DNA is not the principal target in the mechanism of cytotoxicity of these compounds. Importantly, the Ru-CQ complexes are generally less toxic toward normal mouse splenocytes and human foreskin fibroblast cells than the standard antimalarial drug CQDP and therefore this type of compound shows promise for drug development.     

The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways

An investigation of the molecular mechanism of the anticancer activity demonstrated by the ruthenium(II)–arene compound [Ru(η⁶-p-cymene)Cl₂(pta)] (pta is 1,3,5-triaza-7-phosphaadamantane), termed “RAPTA-C”, in Ehrlich ascites carcinoma (EAC) bearing mice is described. RAPTA-C exhibits effective cell growth inhibition by triggering G₂/M phase arrest and apoptosis in cancer cells. Cell cycle arrest is associated with increased levels of p21 and reduced amounts of cyclin E. RAPTA-C treatment also enhances the levels of p53, and its treatment triggers the mitochondrial apoptotic pathway, as shown by the change in Bax to Bcl-2 ratios, resulting in cytochrome c release and caspase-9 activation. c-Jun NH₂-terminal kinase (JNK) is a critical mediator in RAPTA-C-induced cell growth inhibition. Activation of JNK by RAPTA-C increases significantly during apoptosis. Overall, these results suggest a critical role for JNK and p53 in RAPTA-C-induced G₂/M arrest and apoptosis of EAC-bearing mice. Consequently, RAPTA-C treatment results in a significant inhibition in the progression of cancer in an animal model, which emulates the human disease, and does so with remarkably low general toxicity; hence, RAPTA-C has potential for clinical application.     

Syntheses, spectroscopic properties and crystal structures of two organoruthenium (II) complexes of bipyridines: [{Cp*Ru(2,2′-bipy)}2(μ-Cl)][PF6] and [{(η-p-cymene)Ru}2(μ-OH)2(4,4′-bipy)]2[BF4]4

Interaction of [Cp*RuCl(μ-Cl)]₂ with 2,2′-bipyridine (2,2′-bipy) in the presence of Na[PF₆] gave a chloride bridging dinuclear complex [{Cp*Ru(2,2′-bipy)}₂(μ-Cl)][PF₆] (1). In the crystal structure, the cation [{Cp*Ru(2,2′-bipy)}₂(μ-Cl)]⁺ contains a bent Ru-Cl-Ru linkage with an angle of 141.87(12)°. The tris(μ-hydroxo)diruthenium complex [{(η⁶-p-cymene)Ru}₂(μ-OH)₃][BF₄] in acetone solution was treated by 4,4′-bipyridine (4,4′-bipy) to give a hydroxo-bridged tetranuclear complex [{(η⁶-p-cymene)Ru}₂(μ-OH)₂(μ-4,4′-bipy)]₂[BF₄]₄ (2). Complex 2 consists of four (η⁶-p-cymene)Ru moieties connected by two 4,4′-bipy and four hydroxo-bridging groups, forming a novel metallomacrocycle with alternating hydroxyl and 4,4′-bipy bridges between the ruthenium atoms. Spectroscopic properties along with electrochemistry of two organoruthenium (II) complexes 1 and 2 are reported.     

Synthesis and characterization of iron and ruthenium complexes bearing P-N ligands based on 8-hydroxyquinoline

The synthesis of bidentate aminophosphine ligands (PN^quin) based on 8-hydroxyquinoline is described. These ligands react with cis-Fe(CO)₄Br₂ to give selectively octahedral complexes of the type cis,cis-Fe(PN^quin)(CO)₂Br₂. There is only one isomer formed where the two CO and the two bromide ligands adopt a cis configuration. The reaction of [RuCp(CH₃CN)₃]PF₆ with PN^quin ligands affords the halfsandwich complexes [RuCp(PN^quin)(CH₃CN)]PF₆ in high isolated yields. Likewise, treatment of [Ru(η⁶-p-cymene)(μ-Cl)Cl]₂ with PN^quin in the presence of AgCF₃SO₃ affords halfsandwich complexes of the type [Ru(η⁶-p-cymene)(PN^quin)Cl]CF₃SO₃. All ligands and complexes are characterized by NMR and IR spectroscopy. The X-ray structure of representative compounds is reported. In addition, the relative stability of isomeric structures and conformers of Fe(PN^quin-Ph)(CO)₂Br₂ is studied by means of DFT calculations.     

Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action

The reaction of metallothionein-2 (MT-2) with the organometallic antitumour compound [Ru(η(6)-p-cymene)Cl(2)(pta)], RAPTA-C, was investigated using ESI MS and ICP AES. The studies were performed in comparison to cisplatin and significant differences in the binding of the two complexes were observed. RAPTA-C forms monoadducts with MT-2, at variance with cisplatin, that has been observed to form up to four adducts. These data, combined with ICP AES analysis, show that binding of both RAPTA-C and cisplatin to MT-2 requires the displacement of an equivalent amount of zinc, suggesting that Cys residues are the target binding sites for the two metallodrugs. The competitive binding of RAPTA-C and cisplatin towards a mixture of ubiquitin (Ub) and MT-2 was also studied, showing that MT-2 can abstract RAPTA-C from Ub more efficiently than it can abstract cisplatin. The mechanistic implications of these results are discussed.     

New dinuclear arene ruthenium complexes with P,S- or P,O-chelating ligands

Two equivalents of 2-diphenylphosphinobenzoic acid react with 1,2-ethanedithiol and 1,8-diaminonaphthalene under peptidic coupling conditions to give the new ligands 1,2-bis-S-[2^′-(diphenylphosphino)benzoyl]dithioethane (dppte) (1) and 1,2-bis-N-[2^′-(diphenylphosphino)benzoyl]diaminonaphthalene (dppan) (2), respectively. 1 and 2 have been characterised by mass spectrometry, elemental analysis, NMR, IR spectroscopy, and by single-crystal X-ray structure analysis. 2 is easily oxidised by air to give the monophosphine oxide derivatives (3). Single-crystal X-ray structure analysis of 3 shows an intramolecular hydrogen bond between an amido and the phosphoryl oxygen atom. Compounds 1 and 2 react with [RuCl₂(η⁶-p-cymene)]₂ to give the dinuclear complexes [RuCl(η⁶-p-cymene)(dppte)RuCl(η⁶-p-cymene)]²⁺ (4) and [RuCl(η⁶-p-cymene)(dppan)RuCl(η⁶-p-cymene)]²⁺ (5). As determined by single-crystal X-ray structure analysis, 4 and 5 adopt different coordination modes to the ruthenium atoms. In 4 the symmetric dppte ligand is P,S coordinated to the ruthenium atom, whereas in 5 the dppan ligand prefers a P,O coordination mode.     

Metal complexes of natural melophlins and their cytotoxic and antibiotic activities

Complexes of the natural melophlins A and C with Mg, Zn, Ga, La and Ru were prepared, characterized and tested for antimicrobial and cytotoxic effects. The lanthanum complex La(melophlinato C)₃ and the ruthenium complex chlorido(η⁶-p-cymene)(melophlinato C)ruthenium(II) inhibited cells of human A-498 kidney cancer at IC₅₀ = 0.54 μM and 1.0 μM, respectively, and so distinctly better than free melophlin C. Another synergistic effect of coordinating melophlins to bioactive metals was found in the growth inhibition of the melophlin C-resistant bacterium Micrococcus luteus by Ga, La and Ru complexes of melophlin C.     

Metal–drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells

In our ongoing search for new metal-based chemotherapeutic agents against leishmaniasis and Chagas disease, six new ruthenium–ketoconazole (KTZ) complexes have been synthesized and characterized, including two octahedral coordination complexes—cis,fac-[Ru^IICl₂(DMSO)₃(KTZ)] (1) and cis-[Ru^IICl₂(bipy)(DMSO)(KTZ)] (2) (where DMSO is dimethyl sulfoxide and bipy is 2,2′-bipyridine)—and four organometallic compounds—[Ru^II(η⁶-p-cymene)Cl₂(KTZ)] (3), [Ru^II(η⁶-p-cymene)(en)(KTZ)][BF₄]₂ (4), [Ru^II(η⁶-p-cymene)(bipy)(KTZ)][BF₄]₂ (5), and [Ru^II(η⁶-p-cymene)(acac)(KTZ)][BF₄] (6) (where en is ethylenediamine and acac is acetylacetonate); the crystal structure of 3 is described. The central hypothesis of our work is that combining a bioactive compound such as KTZ and a metal in a single molecule results in a synergy that can translate into improved activity and/or selectivity against parasites. In agreement with this hypothesis, complexation of KTZ with Ru^II in compounds 3–5 produces a marked enhancement of the activity toward promastigotes and intracellular amastigotes of Leishmania major, when compared with uncomplexed KTZ, or with similar ruthenium compounds not containing KTZ. Importantly, the selective toxicity of compounds 3–5 toward the leishmania parasites, in relation to human fibroblasts and osteoblasts or murine macrophages, is also superior to the selective toxicities of the individual constituents of the drug. When tested against Trypanosoma cruzi epimastigotes, some of the organometallic complexes displayed activity and selectivity comparable to those of free KTZ. A dual-target mechanism is suggested to account for the antiparasitic properties of these complexes.     

Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action

Neutral and cationic organometallic ruthenium(II) piano stool complexes of the type [(η⁶-cymene)RuCl(X)(Y)] (complexes R1-R8) has been synthesized and characterized. In cationic complexes, X, Y is either a η² phosphorus ligand such as 1,1-bis(diphenylphosphino)methane (DPPM) and 1,2-bis(diphenylphosphino)ethane (DPPE) or partially oxidized ligands such as 1,2-bis(diphenylphosphino)methane monooxide (DPPMO) and 1,2-bis(diphenylphosphino)ethane monooxide (DPPEO) which are strong hydrogen bond acceptors. In neutral complexes, X is chloride and Y is a monodentate phosphorous donor. Complexes with DPPM and DPPMO ligands ([(η⁶-cymene)Ru(η²-DPPM)Cl]PF₆ (R2), [(η⁶-cymene)Ru(η²-DPPMO)Cl]PF₆ (R3), [(η⁶-cymene)Ru(η¹-DPPM)Cl₂] (R5) and [(η⁶-cymene)Ru(η¹-DPPMO)Cl₂] (R6) show good cytotoxicity. Growth inhibition study of several human cancer cell lines by these complexes has been carried out. Mechanistic studies for R5 and R6 show that inhibition of cancer cell growth involves both cell cycle arrest and apoptosis induction. Using an apoptosis PCR array, we identified the sets of anti-apoptotic genes that were down regulated and pro-apoptotic genes that were up regulated. These complexes were also found to be potent metastasis inhibitors as they prevented cell invasion through matrigel. The complexes were shown to bind DNA in a non intercalative fashion and cause unwinding of plasmid DNA in cell-free medium by competitive ethidium bromide binding, viscosity measurements, thermal denaturation and gel mobility shift assays.     

Metabolization of [Ru(η6-C6H5CF3)(pta)Cl2]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand

Abstract  

The anticancer ruthenium–arene compound [Ru(η⁶-C₆H₅CF₃)(pta)Cl₂] (where pta is 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane), termed RAPTA-CF3, with the electron-withdrawing α,α,α-trifluorotoluene ligand, is one of the most cytotoxic RAPTA compounds known. To rationalize the high observed cytotoxicity, the hydrolysis of RAPTA-CF3 in water and brine (100 mM sodium chloride) and its reactions with the protein ubiquitin and a double-stranded oligonucleotide (5′-GTATTGGCACGTA-3′) were studied using NMR spectroscopy, high-resolution Fourier transform ion cyclotron resonance mass spectrometry, and gel electrophoresis. The aquation of the ruthenium–chlorido complex was accompanied by a loss of the arene ligand, independent of the chloride concentration, which is a special property of the compound not observed for other ruthenium–arene complexes with relatively stable ruthenium–arene bonds. Accordingly, the mass spectra of the biomolecule reaction mixtures contained mostly [Ru(pta)]–biomolecule adducts, whereas [Ru(pta)(arene)] adducts typical of other RAPTA compounds were not observed in the protein or DNA binding studies. Gel electrophoresis experiments revealed a significant degree of decomposition of the oligonucleotide, which was more pronounced in the case of RAPTA-CF3 compared with RAPTA-C. Consequently, facile arene loss appears to be responsible for the increased cytotoxicity of RAPTA-CF3.     

From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands

The synthesis, characterization, reactivity and in vitro anticancer activity of a series of Ru^II-arene complexes with carbohydrate-derived phosphite and biscarboxylato co-ligands are reported. The compounds were characterized by NMR spectroscopy and electrospray ionization (ESI) mass spectrometry, and the molecular structures of oxalato(η⁶-p-cymene)(3,5,6-bicyclophosphite-1,2-O-isopropylidene-α-D-glucofuranoside)ruthenium(II) and oxalato(η⁶-p-cymene)(3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-α-D-glucofuranoside)ruthenium(II) were determined by X-ray diffraction analysis. In contrast to their dichlorido counterparts, the biscarboxylato complexes did not exhibit significant reactivity towards biomolecules, such as cysteine, methionine, ubiquitin or the DNA model 5′-GMP, and resist hydrolysis; no hydrolytic species were detected by ¹H and ³¹P{¹H} NMR spectroscopy over several days. These structural alterations led to a decrease in the tumor-inhibiting potency of the compounds in human cancer cell lines.     

In vitro leishmanicidal activity and theoretical insights into biological action of ruthenium(II) organometallic complexes containing anti-inflammatories

Leishmaniasis, a neglected tropical disease caused by protozoans of the genus Leishmania, kills around 20–30 thousand people in Africa, Asia, and Latin America annually and, despite its potential lethality, it can be treated and eventually cured. However, the current treatments are limited owing to severe side effects and resistance development by some Leishmania. These factors make it urgent to develop new leishmanicidal drugs. In the present study, three ruthenium(II) organometallic complexes containing as ligands the commercially available anti-inflammatories diclofenac (dic), ibuprofen (ibu), and naproxen (nap) were synthesized, characterized, and subjected to in vitro leishmanicidal activity. The in vitro cytotoxicity assays against Leishmania (L.) amazonensis and Leishmania (L.) infantum promastigotes have shown that complexes [RuCl(dic)(η⁶-p-cymene)] (1) and [RuCl(nap)(η⁶-p-cymene)] (3) were active against both Leishmania species. Complex [RuCl(ibu)(η⁶-p-cymene)] (2) has exhibited no activity. The IC₅₀ values for the two active complexes were respectively 7.42 and 23.55 μM, for L. (L.) amazonensis, and 8.57 and 42.25 μM, for L. (L.) infantum. Based on the toxicological results and computational analysis, we proposed a correlation between the complexes and their activity. Our results suggest both complexation to ruthenium(II) and ligands structure are key elements to leishmanicidal activity.     

Synthesis, structure, and characterization of some ruthenium arene complexes of N-(arylmethylene)-2-(methylthio)anilines and 2-(methylthio)aniline

A series of cationic, half-sandwich ruthenium complexes with the general formula [(η⁶-p-cymene)RuCl(MeSC₆H₄2-NCHAr)][PF₆] (3a-h), have been prepared from the reaction of [(η⁶-p-cymene)RuCl₂]₂ with various N,S-donor Schiff base ligands derived from 2-(methylthio)aniline and several substituted benzaldehydes. The related aniline complex [(η⁶-p-cymene)RuCl(MeS-C₆H₄-2-NH₂)][PF₆] (4) was synthesized from 2-(methylthio)aniline. All of the ruthenium complexes were characterized by IR, ¹H NMR, and UV/Vis spectroscopies. The molecular structure of complex 4 was determined by X-ray crystallography.     

Short-bite aminobis(phosphonite) containing olefinic functionalities, PhN{P(OC6H3(OMe-o)(C3H5-p))2}2: Synthesis and transition metal complexes

Short-bite aminobis(phosphonite) containing olefinic functionalities, PhN{P(OC₆H₃(OMe-o)(C₃H₅-p))₂}₂ (1) was synthesized by reacting PhN(PCl₂)₂ with eugenol in the presence of triethylamine. The ligand 1 acts as a bidentate chelating ligand toward metal complexes [M(CO)₄(C₅H₁₀NH)₂] forming [M(CO)₄{η²-PhN{P(OC₆H₃(OMe-o)(C₃H₅-p))₂}₂}] (M = Mo, 2; W, 3). The reaction between 1 and [CpFe(CO)₂]₂ leads to the cleavage of one of the P-N bonds due to the metal assisted hydrolysis to give a mononuclear complex [CpFe(CO){P(O)(OC₆H₃(OMe-o)(C₃H₅-p))₂}{PhN(H)(P(OC₆H₃(OMe-o)(C₃H₅-p))₂)}] (4). Treatment of 1 with gold(I) derivative, [AuCl(SMe₂)] resulted in the formation of a dinuclear complex, [(AuCl)₂{PhN{P(OC₆H₃(OMe-o)(C₃H₅-p))₂}₂}] (5) with a Au···Au distance of 3.118(2) Å indicating the possibility of aurophilic interactions. An equimolar reaction between 1 and [Ru(η⁶-p-cymene)Cl₂]₂ afforded a tri-chloro-bridged bimetallic complex [(η⁶-p-cymene)Ru(μ-Cl)₃Ru{PhN(P(OC₆H₃(OMe-o)(C₃H₅-p))₂)₂}Cl] (6). The crystal structures of 1-3 and 5 were established by single crystal X-ray diffraction studies.     

Dinuclear ruthenium complexes containing tripodal dithiophosphonate ligands

Treatment of [(η⁶-p-cymene)RuCl(μ-Cl)]₂ with Lawesson’s reagent [ArP(S)(μ-S)]₂ (Ar = p-C₆H₄OMe) in the presence of ammonium hydroxide afforded the dinuclear complex [(η⁶-p-cymene)Ru{μ-η¹(S),η²(S,S′)-ArP(O)S₂}]₂ (1) in which the tripodal [ArP(O)S₂]²⁻ ligands bind to the ruthenium atom in both bridging and chelating modes with two non-coordinating PO groups. Interaction of [RuHCl(CO)(PPh₃)₃] with [ArP(S)(μ-S)]₂ and bis(diphenylphosphino)methane (dppm) in the presence of ammonium hydroxide gave the dinuclear complex [Ru(CO){μ₃-η¹(O),η²(S,S′)-ArP(O)S₂}(dppm)]₂ (2) in which the tripodal [ArPOS₂]²⁻ ligands bind the two Ru atoms via both sulfur and oxygen atoms. Treatment of [Ru(PPh₃)₃Cl₂] with [ArP(S)(μ-S)]₂ at reflux in the presence of ammonium hydroxide led to the formation of the dinuclear mixed valence complex [Ru₂Cl₂(μ-S){μ₃-η¹(O),η¹(S),-η²(S,S′)-ArP(O)S₂}(PPh₃)₃] (3), which contains a [Ru^II(PPh₃)₂Cl]⁺ and [Ru^IV(PPh₃)Cl]³⁺ moieties by the tripodal [ArPOS₂]²⁻ ligand in a μ₃-η¹(O),η¹(S),η²(S,S′) coordination mode and the μ-S²⁻ anion. The crystal structures of 1, 2, and 3·CH₂Cl₂ along with their spectroscopic and electrochemical properties are reported.     

Organometallic Half-Sandwich Dichloridoruthenium(II) Complexes with 7-Azaindoles: Synthesis,Characterization and Elucidation of Their Anticancer Inactivity against A2780 Cell Line

A series of organometallic half-sandwich dichloridoruthenium(II) complexes of the general formula [Ru(η ⁶-p-cym)(naza)Cl₂] (1–8; p-cym = p-cymene; naza = 7-azaindole or its derivatives) was synthesised and fully characterized by elemental analysis, mass spectrometry, and infrared and multinuclear NMR spectroscopy. A single-crystal X-ray structural analysis of [Ru(η ⁶-p-cym)(2Me4Claza)Cl₂] (6) revealed a typical piano-stool geometry with an N7-coordination mode of 2-methyl-4-chloro-7-azaindole (2Me4Claza). The complexes have been found to be inactive against human ovarian cancer cell line A2780 up to the highest applied concentration (IC₅₀ > 50.0 μM). An inactivity of the complexes is caused by their instability in water-containing solvents connected with a release of the naza N-donor ligand, as proved by the detailed ¹H NMR, mass spectrometry and fluorescence experiments.     

Synthesis of Ru-Arene complexes of Me-Duphos. X-ray, PGSE NMR diffusion and catalytic studies

Cationic [RuCl(arene)(Me-Duphos)]Cl complexes, arene=η⁶-benzene and η⁶-p-cymene, Me-Duphos=1,2-bis-((2R,5R)-2,5-dimethylphospholano) benzene) have been prepared and studied by X-ray crystallography and NMR spectroscopy. PGSE NMR diffusion studies have been used to recognize (a) ion pairing as a function of solvent and (b) larger molecular volumes. Several arene-Ru-complexes have been shown to be useful catalyst precursors in the hydrolysis of terminal aryl alkynes to afford acetophenones.